The first snake antivenom produced, against the Indian Cobra. Immunotherapy with animal-derived antivenom has continued to be the main treatment for snakebite envenoming for 120 years.


The Fav-Afrique antivenom, produced by Sanofi Pasteur (France) permanently discontinued.


World Health Organization (WHO) lists snakebite envenoming as a neglected tropical disease



WHO launches a strategy to prevent and control snakebite envenoming, including a program targeting affected communities and their health systems

SRPNTS launched.

in 2019 with £9 million funding from the UK government through the Department for International Development (DFID) through March 2021


WHO neglected tropical disease.

In 2018, snakebite envenoming (SBE) was officially recognized as a Neglected Tropical Disease (NTD) by the World Health Organization (WHO). This led to the development and launch, in May 2019, of their official snakebite strategy document; ‘Snakebite Envenoming – A Strategy for Prevention and Control’, which outlines the key strategy and actions required to reach their target of reducing deaths and disabilities associated with snakebite by 50% by 2030

The strategy is based on four strategic objectives; 

  1. Empower and engage communities,

  2. Ensure safe, effective treatments, 

  3. Strengthen Health systems,

  4. Increase partnership, coordination and resources. 


These objectives are separated into three distinct phases (figure 1):

  1. The Pilot,

  2. Scale-up,

  3. Full roll-out.


To achieve this goal the WHO estimates that it will cost $136.76M between 2019 and 2030.

The strategic objectives, target, and implementation phases within the WHO SBE strategy

Figure 1 - the strategic objectives, target, and implementation phases within the WHO SBE strategy